title: Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia.
abstract: Essential thrombocythaemia (ET) is a heterogeneous disorder with respect to plasma erythropoietin concentration at diagnosis and clonality of haematopoiesis. Polycythaemia rubra vera-1 (PRV-1) positivity, i.e. PRV-1 mRNA overexpression, is known to be present in the vast majority of patients with polycythaemia vera and also in some patients with ET. In the present study, PRV-1 expression was quantified by real-time polymerase chain reaction in 70 ET patients; 17 of them (24%) were found to be PRV-1 positive. Ten of the 17 PRV-1 positive ET patients had experienced thromboembolic complications compared with 14 of 53 PRV-1 negative patients, the difference between the two groups being statistically significant (P=0.02). In addition, the frequency of total vascular complications, thromboembolic events and major bleedings, was significantly higher in the group of PRV-1 positive as compared with PRV-1 negative ET patients (P=0.03). The time from diagnosis of ET to the requirement of platelet-lowering therapy was significantly shorter in PRV-1 positive compared with PRV-1 negative ET patients (P=0.014). It can be concluded that PRV-1 positive patients appear to suffer from a more aggressive disorder with increased risk for vascular complications and a greater need for platelet-lowering therapy, compared with PRV-1 negative ET patients.
authors: Haematology and Coagulation Section, Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
authors: Peter
authors: P
authors: Johansson
authors: Anne
authors: A
authors: Ricksten
authors: Lovisa
authors: L
authors: Wennström
authors: Lars
authors: L
authors: Palmqvist
authors: Jack
authors: J
authors: Kutti
authors: Björn
authors: B
authors: Andréasson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D058851:GPI-Linked Proteins; D006801:Humans; D007519:Isoantigens; D008297:Male; D008562:Membrane Glycoproteins; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis*; D011956:Receptors, Cell Surface / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000097:blood* / Q000188:drug therapy; D013923:Thromboembolism / Q000188:drug therapy / Q000235:genetics*
chemical_list: C407242:CD177 protein, human; D058851:GPI-Linked Proteins; D007519:Isoantigens; D008562:Membrane Glycoproteins; D010975:Platelet Aggregation Inhibitors; D012333:RNA, Messenger; D011956:Receptors, Cell Surface